Dublin, July 15, 2021 (GLOBE NEWSWIRE) – The report “Global Dry Eye Drugs Market Opportunities & Strategies Through 2030: The Impact And Recovery From COVID-19” has been added ResearchAndMarkets.com to offer.
The global dry eye drug market is expected to grow from $ 2,892.8 million in 2015 to $ 3,245.6 million in 2020, with an average annual growth rate (CAGR) of 2.3%.
The market is expected to grow with a CAGR of 8.2% to nearly $ 4,806.0 million by 2025 and to grow to $ 6,329.7 million by 2030 with a CAGR of 5.7%.
The growth over the historical period resulted from an aging population, an increasing number of contact lens wearers, an increase in disposable income, an increase in the number of treatment options, an increase in allergies, an increase in unhealthy or improper diets, and the prevalence of diabetes mellitus. Factors that negatively affected growth over the historical period were poor access to health care and a lack of awareness of dry eye drugs.
Going forward, growth will be driven by the increase in laser surgery, increasing screen time, busy lifestyles, increasing exposure to diabetes, increasing prevalence of dry eye diseases, a promising pipeline for dry eye diseases, and side effects of other drugs. Factors that could hamper the growth of the dry eye drugs market in the future include long and costly drug approvals, strict rules and regulations, and disruptions in the supply chain of dry eye drugs due to the effects of Covid-19.
The Dry Eye Drugs market is segmented into Aqueous, Evaporative, and Aqueous and Evaporative by product type. The Aqueous & Evaporative Supplements market was the largest segment of the Dry Eye Drugs market segmented by Product Type, accounting for $ 2,670.9 million, or 82.3% of total volume, in 2020. The evaporation market is expected to be the fastest growing segment in the future at a CAGR of 8.9% over the 2020-2025 period.
The dry eye medication market is divided into hospital pharmacies, eye clinics, retail pharmacies, and online pharmacies based on the type of distribution channel. Retail pharmacies were the largest segment of the dry eye medication market, segmented by distribution channels, accounting for $ 2,063.9 million, or 63.6% of total volume, in 2020. The online pharmacy market is expected to be the fastest growing segment with a CAGR of 14.3%.
The dry eye medication market is divided into OTC medication and prescription medication by prescription medication. OTC drugs were the largest segment of the dry eye drugs market broken down by prescription type, accounting for $ 1,723.1 million, or 53.1% of total volume, in 2020. The Prescription Drugs market is expected to be the fastest growing segment with a CAGR of 10.1% over the 2020-2025 period.
The dry eye medication market is divided into branded and generic drugs based on drug variation. The Branded Drugs segment was the largest segment of the dry eye drugs market segmented by drug variation, accounting for $ 2,070.7 million, or 63.8% of the total, in 2020. In the future, it is expected that generics will be the fastest growing segment in a CAGR. will be of 10.3% in the period 2020-2025.
The dry eye medication market is divided into liquid drops, gel, eye ointment, and others according to the systems of administration. The Liquid Drops were the largest segment of the Dry Eye Drugs market segmented by system of delivery, accounting for $ 3,164.8 million, or 97.5% of the total, in 2020. The eye ointment market is expected to be the fastest growing segment with a CAGR of. its 23.2%.
North America was the largest region in the market for dry eye drugs, accounting for 31.3% of the global market in 2020. It was followed by the Asia-Pacific region, Western Europe, and then the other regions. Going forward, the fastest growing regions in the dry eye drug market will be the Middle East and Africa, where growth will be at CAGRs of 20.2% and 12.1%, respectively. This is followed by Western Europe and North America, where the markets are expected to grow with CAGRs of 8.3% and 7.6% respectively.
The dry eye medication market is highly concentrated, with a small number of large players. The top ten competitors in the market accounted for 78.16% of the total market in 2019. Major players in the market include Allergan plc, Alcon Inc, Bausch Health Companies Inc., Novartis AG, Otsuka Holdings Co, Ltd. and other.
Key topics covered:
1. Summary of Dry Eye Drugs Market Summary
2. Table of contents
3. List of figures
4. List of tables
5. Reporting structure
7. Market Characteristics for Drugs for Dry Eye Drugs
7.1. Market definition
7.2. Market segmentation by prescription type
7.2.1. OTC drugs
7.2.2. Prescription drugs
7.3. Market segmentation by drug variation
7.4. Market segmentation by product type
7.4.3. Watery and evaporating
7.5. Market segmentation by sales channel
7.5.1. Hospital pharmacies
7.5.2. Eye clinics
7.5.3. Retail pharmacies
7.5.4. Online pharmacies
7.6. Market segmentation according to delivery system
8. Analysis of the supply chain of the dry eye medicine market
8.1. Raw material suppliers
8.2. Contract Research Organization (CRO)
8.3. Manufacturer of drugs for dry eyes
8.3.1. Drug research
8.3.2. Preclinical and clinical studies
8.3.3. Patents after discovery and approval
8.3.4. Drug manufacturing
8.4. Contract Manufacturing Organization (CMO)
8.5. Wholesalers / distributors
8.6. Retailers (pharmacies) and hospitals
8.7. Ophthalmologists and opticians
9. Dry Eye Drugs Market Product Analysis – Product Examples
10. PVA TEARST
10.1.1. Santen Pharmaceutical Co., Ltd.
10.1.2. Sun Pharmaceuticals Industries, Ltd.
11. Customer Briefing for Dry Eye Drugs Market
11.1. Dry eye conditions in contact lens wearers and non-lens wearers
11.2. Vision loss is the main concern for glaucoma patients
11.3. The majority of patients do not seek preventive eye care
11.4. Effects of dry eye (DED) on patient quality of life
11.5. Two-thirds of Americans have eye problems
12. Dry Eye Drugs Market Trends and Strategies
12.1. Single dose eye drops without preservatives
12.2. Development of new delivery systems
12.3. New product development
12.4. Increasing research and collaborations
12.5. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) used to treat dry eye
12.6. Development of combination therapies
12.7. Global expansion and acquisitions
12.8. Integration of modern techniques
12.9. Nasal spray therapeutics for the treatment of dry eye
13. Impact of COVID-19 on Dry Eye Drugs Market
13.1. Consumer perception
13.2. Occurrence of conjunctivitis in COVID-19 patients
13.3. Medications used in COVID-19 patients are likely to develop eye risks
13.4. Effect of screens
13.5. Serious eye abnormalities
14. Unmet need in the market for dry eye drugs
14.1. Diagnostic challenges that lead to wrong treatment decisions
14.2. Low coverage for dry eye medication
14.3. Differences in the availability of drugs for dry eye in countries
14.4. Poor compliance and high dropout rates for dry eye medication
15. Dry Eye Drugs Market Price Analysis
15.1. Price analysis of prescription drugs
15.2. Price analysis of over-the-counter drugs
16. Overview of dry eye, symptoms and treatment options
16.1. Overview of the dry eye
16.2. Causes and Symptoms of Dry Eye Eye
16.3. Treatment options for dry eye
16.3.1. Mild dry eye symptoms
16.3.2. Moderate dry eye symptoms
16.3.3. Moderate to severe dry eye symptoms
- Santen Pharmaceutical Co., Ltd.
- Sentiss Pharma Pvt. GmbH.
- OASIS Medical, Inc.
- VISUfarma BV
- Sun Pharmaceutical Industries Limited
- Bayer AG
- Johnson & Johnson
- Daiichi Sankyo
- ERC Labs
- Eyesight gain
- Medicom healthcare
- Implandata ophthalmic products GmbH
- The Geuder Group
- Aflofarm Pharmacy Poland
- VUAB Pharma, Inc.
- Endo International plc
- Aurinia Pharmaceuticals Inc
- Thomas Eye Group
- Alimera Sciences
- eye patch
- Eyepoint Medicines
- Gama vision
- Biolab Pharma
- Novaliq GmbH
- Horus Pharma
- Prestige Consumer Healthcare, Inc
- Azura Ophthalmics, Ltd
- Hoya Corporation
- Adcock Ingram
Please visit https://www.researchandmarkets.com/r/is6mzb for more information on this report